Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

694 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism.
van Agteren M, Armstrong VW, van Schaik RH, de Fijter H, Hartmann A, Zeier M, Budde K, Kuypers D, Pisarski P, Le Meur Y, van der Werf M, Mamelok RD, Oellerich M, van Gelder T. van Agteren M, et al. Among authors: budde k. Ther Drug Monit. 2008 Aug;30(4):439-44. doi: 10.1097/FTD.0b013e318180c709. Ther Drug Monit. 2008. PMID: 18641546 Clinical Trial.
Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients.
Vítko S, Margreiter R, Weimar W, Dantal J, Kuypers D, Winkler M, Øyen O, Viljoen HG, Filiptsev P, Sadek S, Li Y, Cretin N, Budde K; RAD B201 Study Group. Vítko S, et al. Among authors: budde k. Am J Transplant. 2005 Oct;5(10):2521-30. doi: 10.1111/j.1600-6143.2005.01063.x. Am J Transplant. 2005. PMID: 16162203 Free article. Clinical Trial.
CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients.
Hesselink DA, van Schaik RH, van Agteren M, de Fijter JW, Hartmann A, Zeier M, Budde K, Kuypers DR, Pisarski P, Le Meur Y, Mamelok RD, van Gelder T. Hesselink DA, et al. Among authors: budde k. Pharmacogenet Genomics. 2008 Apr;18(4):339-48. doi: 10.1097/FPC.0b013e3282f75f88. Pharmacogenet Genomics. 2008. PMID: 18334918 Clinical Trial.
Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial.
van Gelder T, Silva HT, de Fijter JW, Budde K, Kuypers D, Tyden G, Lohmus A, Sommerer C, Hartmann A, Le Meur Y, Oellerich M, Holt DW, Tönshoff B, Keown P, Campbell S, Mamelok RD. van Gelder T, et al. Among authors: budde k. Transplantation. 2008 Oct 27;86(8):1043-51. doi: 10.1097/TP.0b013e318186f98a. Transplantation. 2008. PMID: 18946341 Clinical Trial.
Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients.
de Winter BC, van Gelder T, Glander P, Cattaneo D, Tedesco-Silva H, Neumann I, Hilbrands L, van Hest RM, Pescovitz MD, Budde K, Mathot RA. de Winter BC, et al. Among authors: budde k. Clin Pharmacokinet. 2008;47(12):827-38. doi: 10.2165/0003088-200847120-00007. Clin Pharmacokinet. 2008. PMID: 19026038
694 results